• Pembrolizumab plus CMP-001 demonstrates efficacy for anti-PD-1 resistant melanoma

    1 day ago - By Healio

    Mohammed Milhem
    The combination of pembrolizumab and CMP-001, an intratumoral toll-like receptor 9 agonist, demonstrated antitumor activity among patients with metastatic melanoma resistant to PD-1 checkpoint inhibition, according to study results presented at American Association for Cancer Research Annual Meeting.
    “Checkpoint inhibition is quickly becoming a key tool for oncologists to treat cancer,”
    Mohammed Milhem, MBBS, clinical professor of internal medicine at University of Iowa, said in a press release. “However, there are many patients that either initially respond to
    Read more ...

     

  • People with lung cancer can live longer if they combine chemo with immune therapy

    2 days ago - By National Post

    Odds of survival can greatly improve for people with the most common type of lung cancer if they are given a new drug that activates the immune system, along with the usual chemotherapy, a major new study has shown.
    The findings, medical experts say, should change the way doctors treat lung cancer: Patients with this form of the disease should receive immunotherapy as early as possible.
    “What it suggests is that chemotherapy alone is no longer a standard of care,” said Dr. Leena Gandhi, a leader of the study and director of the Thoracic Medical Oncology Program at the Perlmutter Cancer...
    Read more ...

     

  • Durvalumab-tremelimumab combination shows antitumor activity in urothelial cancer

    2 days ago - By Healio

    Arjun V. Balar
    The combination of durvalumab and tremelimumab demonstrated antitumor activity among patients with urothelial cancer, according to study results presented at American Association for Cancer Research Annual Meeting.
    The combination also appeared well tolerated.
    “Immunotherapy is active in metastatic urothelial cancer. Durvalumab , a PD-L1 antibody, demonstrated promising safety and activity as part of a phase1/phase 2 trial, which led to the accelerated approval in the postplatinum setting,” Arjun V. Balar, MD, director of the genitourinary medical
    Read more ...